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Abstract: 
As part of our efforts toward clinical translation of GA-198AuNP, our studies are 
focused on therapeutic efficacy of nanoparticulate GA198AuNP agent in dogs with 
prostatic carcinoma. The overall goal is to gain clinical insights on therapeutic 
efficacy of  GA198AuNP in a large animal model. We have performed a phase I 
clinical trial using GA-AuNP administered intravenously or intratumorally by 
injection or infusion.  CT scans were performed prior to injection and 24 hours 
post injection in 3 of the 4 dogs.  Following injections, dogs were allowed further 
treatment as recommended by the primary attending clinician.  Four dogs have 
been treated to date.  Complications related to GA-AuNP treatment were not 
observed, and all 4 dogs received adjunctive treatment with radiation therapy 
and/ or chemotherapy. These preliminary studies have clearly provided 
compelling evidence on the therapeutic potential of biocompatible GA-AuNP for 
their utility as novel therapeutic agents in treating various types of inoperable 
solid tumors. Intra-tumoral and intravenous administration of GA-AuNP is safe in 
dogs with spontaneously occurring tumors.  As further therapeutic efficacy 
studies continue, the outcome of this clinical trial in a large animal model will 
generate therapeutic efficacy data which will be used for filing IND application for 
Phase I clinical trial studies. This clinical translation effort provides significant 
advances in terms of delivering optimum therapeutic payloads into prostate 
cancers with subsequent reduction in tumor volume, thus may effectively 
reduce/eliminate the need for surgical resection.  This presentation will include 
details of clinical translation of GA198AuNP in prostate tumor bearing dogs. 
 
